Skip to main content
AQSTAquestive Therapeutics, Inc.Sell4.2·$3.46
SellModerate Confidence
Investment thesis

AQST shows strong revenue growth and substantial analyst-implied upside, but a death-cross technical breakdown, continued cash burn, and elevated short and options positioning point to significant near-term risk.

Thesis pillars

  • Strong Revenue Growth→Stable
  • Cash Burn Below Risk Floor↓Deteriorating
  • Death Cross Technical Breakdown→Stable
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Jul 5, 2026, based on the 10-K filed Mar 4, 2026· older than 90 days

Full reasoning →

Open full analysis

Aquestive Therapeutics, Inc. (AQST) Stock Analysis

Inst Constrain edge

SellQualityShortModerate Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Sell if holding. Engine safety override at $3.46: Risk below floor (0.8 < 2.5) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 9.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Elevated put/call ratio: 2.53; Below-average business quality.

Aquestive Therapeutics is a specialty pharmaceutical company using its proprietary PharmFilm oral-film and AdrenaVerse epinephrine-prodrug technologies, manufacturing four licensed commercialized products, including Suboxone sublingual film, for which it is the sole and... Read more

QualityF-score4 / 9FCF yield-5.19%
Stop $3.27Analyst target $8.12(−13% haircut)A.R:R 9.5:1
Analyst consensus$9.33+169.7%9 analysts with price targets
$8.12Analyst target
$3.46price
$9.33mean
$11

Sell if holding. Engine safety override at $3.46: Risk below floor (0.8 < 2.5) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 9.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Elevated put/call ratio: 2.53; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.2/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 101d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.

10-K grounded · weekly refresh

About Aquestive Therapeutics, Inc.

About Aquestive Therapeutics, Inc.

Aquestive Therapeutics manufactures Suboxone, the leading branded sublingual film for opioid dependence, as its sole and exclusive supplier to licensee Indivior, alongside three other licensed products and its own FDA-approved CNS therapy Libervant for pediatric seizure clusters. The company's licensed product portfolio generated $44.5 million in revenue during 2025, down from $57.6 million in 2024, while its lead pipeline candidate, the non-device epinephrine film Anaphylm, missed a January 31, 2026 PDUFA date after the FDA issued a Complete Response Letter.

Aquestive earns revenue primarily through manufacturing and royalty payments from licensees that commercialize its PharmFilm-based products, with Suboxone, marketed by Indivior since 2010 and still holding approximately 24% film-based market share against generics, the largest contributor, alongside Sympazan and other licensed film products. The company also sells its own proprietary product, Libervant, a buccal diazepam film for seizure clusters in patients aged two to five, though a February 2025 federal court ruling vacated the FDA's approval for that age group following litigation brought by Neurelis, forcing Aquestive to halt U.S. marketing. All manufacturing takes place at its Portage, Indiana facility, which is inspected by the FDA, DEA, and other health agencies, while research and clinical operations are based in Warren, New Jersey. To fund operations, including the planned Anaphylm resubmission, the company entered a five-year, up-to-$150 million term loan facility with Oaktree Capital Management in May 2026, partly used to repay existing debt, on top of its existing 13.5% notes.

Show full overview

Aquestive's near-term valuation hinges on overturning the FDA's January 30, 2026 Complete Response Letter for Anaphylm, which cited human-factors deficiencies in the pouch-opening and film-placement design rather than the drug's clinical comparability to EpiPen and Auvi-Q, which the CRL left unquestioned. The company has redesigned the packaging and instructions for use and expects to resubmit the NDA in the third quarter of 2026 following new human-factors and pharmacokinetic studies, but no FDA guarantee of accelerated review exists. A second regulatory overhang persists at Libervant, where a February 2025 district court ruling vacated FDA approval for patients aged two to five pending an appeal, tied to Neurelis's Valtoco orphan-drug exclusivity through January 2027.

See also: Healthcare · Drug Manufacturers - Specialty & Generic

From Aquestive Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 18, 2026

Recent Developments — Aquestive Therapeutics, Inc.

Latest item Nov 18, 2026 · Generated 2026-11-22T12:07:31Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Wed, Mar 3, 2027101d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Product: Suboxone
Risk below floor (0.8 < 2.5)

Key Metrics

P/E (TTM)—
P/E (Fwd)-6.0
Mkt Cap$435M
EV/EBITDA-7.3
Profit Mgn-162.3%
ROE—
Rev Growth-41.0%
Beta1.50
DividendNone
Analysts with ratings15

Quality Signals

Piotroski F4/9

Options Flow

P/C2.53bearish
IV94%elevated

Concentration Risks(10-K Item 1A)

  • HIGHProductSuboxone
    10-K Item 1: 'We are the sole and exclusive supplier and manufacturer of Suboxone and have produced over 3.0 billion doses of Suboxone since its launch in 2010.'

Material Events(8-K, last 90d)

  • 2026-05-13Item 1.01MEDIUM
    On May 12, 2026, the company entered a five-year term loan facility of up to $150.0 million with Oaktree Capital Management (Tranche A $55.0 million funded), partly used to repay existing debt.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

4 floor-breakers

Revenue shrinking — -41.0% YoY. Growth thesis broken unless recovery story develops.static

Revenue Growth
0.0
Declining revenue: -41%
Low model confidence on this dimension (33%).

Volatile — 7.1% daily ATR makes tight stops impractical. Position-size conservatively.static

Short Interest
0.0
Days To Cover
0.0
Volatility
0.0
Put Call
0.0
Implied Vol
0.0
Beta
5.0
High short interest: 24%Elevated put/call: 2.53High IV: 94%Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
0.0
Growth Rank
0.0
Value Rank
0.5

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Obv
1.0
Ma Position
1.0
Rsi
3.5
Volume
5.5
Macd
6.3
Volume distribution (falling OBV)Below 200-MA, MA slope -2.0%/30d — confirmed downtrend
GatesMomentum 3.5<4.5A.R:R 9.5 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 101d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Speculative
RSI
40 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MAGOLDEN CROSSSupport $3.37Resistance $4.29

Price Targets

$3
$8
A.Upside+134.7%
A.R:R9.5:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Risk below floor (0.8 < 2.5)
! momentum at 3.5 (below the engine's 4.5 threshold)

Earnings

B
B
M
M
2/4 beats
Next Earnings2027-03-03 (101d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is AQST stock a buy right now?

Sell if holding. Engine safety override at $3.46: Risk below floor (0.8 < 2.5) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 9.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Elevated put/call ratio: 2.53; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $3.27. Score 4.2/10, moderate confidence.

What is the AQST stock price target?

Analyst target: $8.12 (+134.7% upside). Prior stop was $3.27. Stop-loss: $3.27.

What are the risks of investing in AQST?

Concentration risk — Product: Suboxone; Risk below floor (0.8 < 2.5).

Is AQST overvalued or undervalued?

Aquestive Therapeutics, Inc. trades at a P/E of N/A (forward -6.0). TrendMatrix value score: 7.1/10. Verdict: Sell.

What do analysts say about AQST?

15 analysts rate AQST, with a consensus score of 4.2/5. 9 analysts publish price targets averaging $9.

What does Aquestive Therapeutics, Inc. do?Aquestive Therapeutics is a specialty pharmaceutical company using its proprietary PharmFilm oral-film and AdrenaVerse...

Aquestive Therapeutics is a specialty pharmaceutical company using its proprietary PharmFilm oral-film and AdrenaVerse epinephrine-prodrug technologies, manufacturing four licensed commercialized products, including Suboxone sublingual film, for which it is the sole and exclusive manufacturer, plus its own CNS product Libervant. The licensed product portfolio generated $44.5 million in 2025 revenue, down from $57.6 million in 2024, and lead pipeline candidate Anaphylm received an FDA Complete Response Letter on January 30, 2026, delaying its planned launch.

Related stocks: GLAS (Glass House Brands Inc. Subordi) · INDV (Indivior Pharmaceuticals, Inc.) · ANIP (ANI Pharmaceuticals, Inc.) · ETON (Eton Pharmaceuticals, Inc.) · BCRX (BioCryst Pharmaceuticals, Inc.)
Home › Stocks › AQST

Latest news

Latest News

Yahoo Finance102d agoEarnings
Seeking Alpha102d agoEarnings
Yahoo Finance103d ago
TipRanks103d agoEarnings
MarketBeat103d ago
KING5.com103d agoEarnings
MarketBeat103d ago
Yahoo Finance103d agoEarnings
Kalkine Media103d agoFda Decision
MarketBeat103d agoEarnings
TradingView110d agoEarnings
Moomoo108d agoEarnings
Yahoo Finance104d agoProduct
Marketscreener.com104d agoProduct
Investing.com104d agoProduct
Investing.com UK104d ago
Investing.com104d ago
TipRanks104d agoProduct
Fiscal.ai4d ago
Fiscal.ai13d ago
Loading more...